Latest Pharma Insights
Chinese Autoimmune Disease Assets Shine In Latest VC/PE Funding Deals
Artivila, LyncBio, Angel and Accro are among the Chinese biopharma ventures recently raising fresh capital from venture capital and private equity investors, for assets targeting rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis and ulcerative colitis, among others.
Scrip - July 3, 2026
Artivila, LyncBio, Angel and Accro are among the Chinese biopharma ventures recently raising fresh capital from venture capital and private equity investors, for assets targeting rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis and ulcerative colitis, among others.
Scrip - July 3, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
FTC wants AI policy statement input; CRN completes filing briefs with Supreme Court on New York law challenge; NIH announces Supplements Facts First Challenge phase 1 winners; and HBW Insight publishes article packages from AESGP meeting in Berlin and US OTC sunscreen ingredient approval.
HBW Insight - July 3, 2026
FTC wants AI policy statement input; CRN completes filing briefs with Supreme Court on New York law challenge; NIH announces Supplements Facts First Challenge phase 1 winners; and HBW Insight publishes article packages from AESGP meeting in Berlin and US OTC sunscreen ingredient approval.
HBW Insight - July 3, 2026
Chinese Autoimmune Disease Assets Shine In Latest VC/PE Funding Deals
Artivila, LyncBio, Angel and Accro are among the Chinese biopharma ventures recently raising fresh capital from venture capital and private equity investors, for assets targeting rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis and ulcerative colitis, among others.
Scrip - July 3, 2026
Artivila, LyncBio, Angel and Accro are among the Chinese biopharma ventures recently raising fresh capital from venture capital and private equity investors, for assets targeting rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis and ulcerative colitis, among others.
Scrip - July 3, 2026
The Shape Of Her Heart: The Inspiration Behind the DurAVR Valve From Anteris Technologies
Anteris Technologies has developed a next generation transcatheter heart valve for women and other patients with small anatomies in need of valve replacement. The company’s president and director spoke to Medtech Insight about the product’s innovative design and unmet need it aims to address.
Medtech Insight - July 2, 2026
Anteris Technologies has developed a next generation transcatheter heart valve for women and other patients with small anatomies in need of valve replacement. The company’s president and director spoke to Medtech Insight about the product’s innovative design and unmet need it aims to address.
Medtech Insight - July 2, 2026
Execs On The Move: June 22–26, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 2, 2026
UK Healthcare Cyberattacks Surge Tenfold In 2026, But Ransomware Stays Absent
UK healthcare cyberattacks have surged nearly tenfold in early 2026, yet no ransomware has detonated — SonicWall's data points to something potentially more calculated: systematic network reconnaissance targeting unpatched legacy systems and newly built patient portals simultaneously.
Medtech Insight - July 2, 2026
UK healthcare cyberattacks have surged nearly tenfold in early 2026, yet no ransomware has detonated — SonicWall's data points to something potentially more calculated: systematic network reconnaissance targeting unpatched legacy systems and newly built patient portals simultaneously.
Medtech Insight - July 2, 2026
Global Medtech Guidance Tracker: June 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - July 2, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - July 2, 2026
Terumo’s Global RelayPro Recall Tests Aortic Franchise Amid Record Year
Terumo is recalling about 7,000 RelayPro thoracic stent-grafts across 43 countries after four delivery-system failures, three linked to patient deaths during or following surgery. The FDA has deemed it Class I — its most serious — though causality is unconfirmed.
Medtech Insight - July 2, 2026
Terumo is recalling about 7,000 RelayPro thoracic stent-grafts across 43 countries after four delivery-system failures, three linked to patient deaths during or following surgery. The FDA has deemed it Class I — its most serious — though causality is unconfirmed.
Medtech Insight - July 2, 2026
EU Expands MDR WET Exemption List
Over 70 additional well-established technologies will be exempt from clinical investigations, as the EU aims for more flexible and future-proof WET regulation.
Medtech Insight - July 2, 2026
Over 70 additional well-established technologies will be exempt from clinical investigations, as the EU aims for more flexible and future-proof WET regulation.
Medtech Insight - July 2, 2026
Spinal Cord Stimulator Plaintiffs Allege Harm Far Beyond Device Failure
With more than 107,000 adverse event reports filed since 2016, spinal cord stimulators have drawn sharp legal scrutiny—and plaintiffs are alleging not just device failures but unlicensed medical practice by manufacturers' sales representatives.
Medtech Insight - July 2, 2026
With more than 107,000 adverse event reports filed since 2016, spinal cord stimulators have drawn sharp legal scrutiny—and plaintiffs are alleging not just device failures but unlicensed medical practice by manufacturers' sales representatives.
Medtech Insight - July 2, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
FTC wants AI policy statement input; CRN completes filing briefs with Supreme Court on New York law challenge; NIH announces Supplements Facts First Challenge phase 1 winners; and HBW Insight publishes article packages from AESGP meeting in Berlin and US OTC sunscreen ingredient approval.
HBW Insight - July 3, 2026
FTC wants AI policy statement input; CRN completes filing briefs with Supreme Court on New York law challenge; NIH announces Supplements Facts First Challenge phase 1 winners; and HBW Insight publishes article packages from AESGP meeting in Berlin and US OTC sunscreen ingredient approval.
HBW Insight - July 3, 2026
Second Time Lucky For SB’s Byooviz? Relaunch Offers Fresh Start In US Lucentis Biosimilar Market
After Samsung Bioepis ended its US marketing alliance with Biogen for its Byooviz rival to Lucentis, the ranibizumab biosimilar has now been relaunched via new commercialization partner Harrow. But this is not the only Lucentis rival to have experienced such upheaval.
Generics Bulletin - July 2, 2026
After Samsung Bioepis ended its US marketing alliance with Biogen for its Byooviz rival to Lucentis, the ranibizumab biosimilar has now been relaunched via new commercialization partner Harrow. But this is not the only Lucentis rival to have experienced such upheaval.
Generics Bulletin - July 2, 2026
Japan Deal Strengthens EirGenix’s HER2 Biosimilar Story
EirGenix’s Japan licensing deal for EG1206A extends its HER2 biosimilar partnering strategy, adding a regional route to market while the company builds a broader oncology and CDMO operation.
Generics Bulletin - July 2, 2026
EirGenix’s Japan licensing deal for EG1206A extends its HER2 biosimilar partnering strategy, adding a regional route to market while the company builds a broader oncology and CDMO operation.
Generics Bulletin - July 2, 2026
Aurobindo Begins Integration As It Completes Lannett Acquisition
With a recent FTC approval in hand, Aurobindo has completed its deal to acquire Lannett in the US. The completion means that integration activities can begin immediately, with 400 staff, a portfolio of complex generics and a US manufacturing facility transferring to the Indian giant.
Generics Bulletin - July 2, 2026
With a recent FTC approval in hand, Aurobindo has completed its deal to acquire Lannett in the US. The completion means that integration activities can begin immediately, with 400 staff, a portfolio of complex generics and a US manufacturing facility transferring to the Indian giant.
Generics Bulletin - July 2, 2026
How Western Biotechs Are Navigating The China Challenge
As the BIOSECURE Act and proposed investment-screening laws reshape competition, US biotechs debate whether to engage China's surging drug pipeline or differentiate against it, with no industry-wide consensus on the right approach.
In Vivo - July 2, 2026
As the BIOSECURE Act and proposed investment-screening laws reshape competition, US biotechs debate whether to engage China's surging drug pipeline or differentiate against it, with no industry-wide consensus on the right approach.
In Vivo - July 2, 2026